While CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is
getting a lot of attention as this year’s potential wonder therapy, the generics
industry continues to undergo change. Positive change.
Judging by a resurgence of IPO activities since the new year and increasing
product commercialization news in the pharma and biopharma industries,
the future of these industries is clearly on the rise. And as the market for
generics continues to heat up, so too does the role of CMOs as strategic
...
The price of ensuring quality in chemical manufacturing goes far beyond
cost. Hopefully, quality problems are caught before they can affect patients
but even then, such problems can make or break a manufacturing
organization. In the U.S., while it takes significant effort to earn and maintain
...
The roles of Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs) are growing at light speed as pharma, life sciences and biotech firms of all shapes and sizes discover the benefit of outsourcing key functions in the race to get products to commercialization faster ...
The 400 percent increase in the cost of the life-saving allergy treatment EpiPen has gotten its manufacturer, Mylan, into some deep scrutiny – and rightly so. Maybe it’s a combination of greed, market dominance, regulatory requirements and clearly more and more entities taking a share of the profits...
While manufacturing Active Pharmaceutical Ingredients (APIs) is a costly and time-consuming process, there currently is enormous market demand for APIs to address the challenges of an aging population, and an increasing amount of chronic diseases such as cancer, cardiovascular diseases, diabetes and...